Haemonetics Corporation (HAE) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 21 analysts8.3% Below Target
HAE trades 8.3% below Wall Street's consensus target of $80.33.
Current Price$74.17
Average Target$80.33
Target
Current
Low$67.00
Median$85.00
High$89.00
Analyst Target Range
Forward P/E15.0x
(Fair)
PEG Ratio2.61
(Pricey)
Implied Growth+134.8%
(High Growth)
Analyst Spread27.4%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes HAE achieves its forward estimates and maintains a stable P/E multiple of 15.0x. This scenario reflects the blended consensus of 21 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
HAE Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Haemonetics Corporation (HAE) has a Wall Street consensus price target of $80.33, based on estimates from 21 covering analysts. With the stock currently trading at $74.17, this represents a potential upside of +8.3%. The company has a market capitalization of $3.45B.
Analyst price targets range from a low of $67.00 to a high of $89.00, representing a 27% spread in expectations. The median target of $85.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,10 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HAE trades at a trailing P/E of 36.2x and forward P/E of 15.0x. The forward PEG ratio of 2.61 reflects a premium valuation. Analysts expect EPS to grow +134.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $129.30, with bear and bull scenarios of $81.46 and $170.37 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+133.4%
Industry Consensus
Avg Forward P/E
112.1x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TFXTeleflex Incorporated | $5.6B | $127.00 | $144.67 | +13.9% | Buy | 18.9x | 29 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 ITGRInteger Holdings Corporation | $3.1B | $90.96 | $108.00 | +18.7% | Buy | 15.0x | 15 |
 NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
 NNOXNano-X Imaging Ltd. | $109M | $1.67 | $18.00 | +977.8% | Buy | — | 5 |
 BAXBaxter International Inc. | $10.3B | $19.89 | $20.71 | +4.1% | Hold | 10.4x | 36 |
 BDXBecton, Dickinson and Company | $52.2B | $143.98 | $174.81 | +21.4% | Hold | 11.4x | 34 |
 ISRGIntuitive Surgical, Inc. | $144.5B | $406.78 | $597.78 | +47.0% | Buy | 38.9x | 55 |
 GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
 ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
HAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
What is the HAE stock price target for 2026?
The consensus price target for HAE is $80.33, close to the current price of $74.17 (8.3% implied move). Based on 21 analyst estimates, the stock appears fairly valued near current levels.
Is HAE a buy, sell, or hold?
HAE has a consensus rating of "Buy" based on 21 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $80.33 implies 8.3% upside from current levels.
Is HAE stock overvalued or undervalued?
With a forward P/E of 15.0032x, HAE trades at a relatively low valuation. The consensus target of $80.33 implies 8.3% appreciation, suggesting the market may be pricing in risks.
How high can HAE stock go?
The most bullish Wall Street analyst has a price target of $89 for HAE, while the most conservative target is $67. The consensus of $80.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $170 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover HAE stock?
HAE is well covered by analysts, with 21 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 10 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the HAE stock forecast?
The 12-month HAE stock forecast based on 21 Wall Street analysts shows a consensus price target of $80.33, with estimates ranging from $67 (bear case) to $89 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $129, with bear/bull scenarios of $81/$170.
What is HAE's fair value based on fundamentals?
Our quantitative valuation model calculates HAE's fair value at $129 (base case), with a bear case of $81 and bull case of $170. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
What is HAE's forward P/E ratio?
HAE trades at a forward P/E ratio of 15.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 36.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy HAE stock?
HAE appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $80.33 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do HAE price targets vary so much?
HAE analyst price targets range from $67 to $89, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $80.33 consensus represents the middle ground. Our model's $81-$170 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare